CD86 and neoplasm: To this end, stimulation with anti-CD40 antibody, CD40 ligand, or CpG has been shown to enhance the antigen presenting capacity of murine lymphoma cell lines and human tumor B cells via enhancing the expression of MHC-II, costimulatory molecules (mostly CD86 but also CD80) and adhesion molecules (CD54) (21–24).